A Phase 3 interventional study of Triptorelin Pamoate 11.25mg in Prostate Cancer, sponsored by Ipsen. Completed at 12 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-09.
Sponsored by Ipsen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.
Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 13th largest by enrollment, is the only one that started in 2013, is one of 12 in phase 3, and was the 14th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Baptist Health South Florida · Sites in United States
Ages 18+ · Men only
Cancer Research Antwerp · Sites in Belgium
Ages 18+ · Men only
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+ · Men only
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Sites in Spain
Ages 18+
Marco Lorenzo Bonu · Sites in Italy
Ages 18–80 · Men only
By country, each count listing its studies:
triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 13 · Phase 4 6
First in 2002; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 126 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 120 across the 28 interventional studies. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
26 studies in Prostatic Neoplasms by Ipsen: none open now, none under way, none of them phase 3. Of 26 finished, 12 (46%) have results posted.
Among the 26 studies in Prostatic Neoplasms by Ipsen, this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2013, is one of 7 in phase 3, and was the 12th registered.
Ipsen’s Prostatic Neoplasms studies by the year they started, since 2006.
1 of the studies testing triptorelin in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05851547Ottawa Hospital Research InstituteDose Escalation For INtraprostatic LEsions | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies testing triptorelin in Prostatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Ipsen’s 26 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Assess the efficacy and safety of Triptorelin pamoate 3M formulation (11.25mg) when administered by subcutaneous route.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Abnormal haematological, hepatic or renal functions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
11.25mg, SC on Day 1 and Day 92
Drug: Triptorelin Pamoate 11.25mg
Percentage of Subjects Demonstrating Castration at Day 29 and Maintaining Castration at Day 183
Percentage of subjects castrated (i.e. with serum testosterone \<50 ng/dL or 1.735 nmol/L, using the LC-MS/MS method and missing data imputed by immunoassay method (at time points when LC-MS/MS data was planned to be available only) and the proportion with castration maintained at Day 183 (after receiving 2 S.C. administrations of triptorelin pamoate, three months apart); they were calculated along with their respective 95% confidence intervals (CI) using exact methods on the ITT population at Day 29 and on the initially castrated (IC) population at Day 183
Time frame: At Day 29 and 183
Percentage of Subjects Demonstrating Castration Before Administration of the Second Dose
Percentage of subjects demonstrating castration at Day 92 (before administration of the second dose) were also assessed using the LC-MS/MS method and missing data imputed by immunoassay method (at time points when LC-MS/MS data was planned to be available only) and summarised using descriptive statistics on the ITT and IC populations.
Time frame: At Day 92
Probability of Testosterone <50 ng/dL
Probability of testosterone \<50 ng/dL from Day 29 to Day 183 was assessed as a secondary endpoint using the time to event from first administration date to first observed (and subsequently confirmed if assessment not performed at end of study or early withdrawal visits) serum testosterone level ≥50 ng/dL or ≥1.735 nmol/L at or after Day 29, assessed using the LC-MS/MS Method and Missing Data imputed by immunoassay method Kaplan-Meier Analysis. LC-MS/MS: Liquid Chromatography-Tandem Mass Spectrometry
Time frame: Day 29 through Day 183
Percentage of Subjects Demonstrating Castration With Testosterone Level <50 ng/dL at Day 95
Percentage of subjects demonstrating castration at Day 95 (3-4 days after administration of the second dose to assess the suppression of acute-on-chronic effect following the second administration) were also assessed using the LC-MS/MS method and missing data imputed by immunoassay method (at time points when LC-MS/MS data was planned to be available only) and summarised using descriptive statistics on the ITT and IC populations.
Time frame: Day 95
Time to Achieve Castration (Tcast)
Time to castration (Tcast) from first administration date until first observed serum testosterone level \<50 ng/dL or \<1.735 nmol/L evaluated using the immunoassay method only (i.e. defined as the number of days between the injection time at Day 1 and castration achievement)
Time frame: Up to Day 36
Plasma Triptorelin Levels (Cmin)
Minimal triptorelin plasma concentration at the end of each dosage interval just before the next dose injection (Cmin) for Days 92 and 183 were assessed.
Time frame: At Day 92 and 183
Percentage Change in Prostate Specific Antigen (PSA) Levels From Baseline in All Subjects
Serum PSA level was presented throughout the study using descriptive statistics displaying raw values, change from Baseline and percentage change from Baseline at each visit in all subjects from the ITT population only. Additionally, the PSA level was described in subjects with elevated PSA levels (i.e. \>4 ng/mL) at study entry, and the proportion of subjects with normal PSA levels (i.e. \[0-4\] ng/mL) at Day 183 compared to Baseline was presented.
Time frame: From Day 1 (Baseline) to Day 183 (End of study)
Percentage of Subjects With Normal and Abnormal PSA Levels at Day 183 (End of Study Visit)
0-4 ng/mL (normal PSA value) \>4 ng/mL (abnormal PSA levels)
Time frame: At Day 183
Clinically Apparent Tumor Progression
Tumour progression was recorded according to the Investigator's clinical judgement, considering the PSA levels and any other indications of disease; the clinical confirmation might be supplemented by radiological or other investigations or scans if required. The lack of clinically apparent tumour progression was assessed at Day 92 (prior to administration of the second dose) and Day 183 (end of study visit).
Time frame: Day 92 and 183
Percentage of Subjects With Adverse Events
Time frame: Up to Day 183
Time to Cmax (Tmax) of Triptorelin
Time frame: At 1, 2, 3, 4, 5, 6, 7, 8 and 24 hours after first dose on Day 1
Peak Plasma Concentration Value (Cmax) of Triptorelin
Time frame: At 1, 2, 3, 4, 5, 6, 7, 8 and 24 hours after first dose on Day 1
Area Under the Concentration Versus Time Curve Between 0 and 24 Hours (AUC0-24) of Triptorelin
Time frame: At 1, 2, 3, 4, 5, 6, 7, 8 and 24 hours after first dose on Day 1
Cmin of Triptorelin in Subset of 18 Subjects
Time frame: At Day 92 and 183
| Milestone | Triptorelin Pamoate |
|---|---|
| Started | 126 |
| Completed | 117 |
| Not completed | 9 |
| Withdrew: Adverse event, fatal | 1 |
| Withdrew: Lack of efficacy | 3 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Consent withdrawn | 2 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Other | 1 |
Percentage of subjects castrated (i.e. with serum testosterone \<50 ng/dL or 1.735 nmol/L, using the LC-MS/MS method and missing data imputed by immunoassay method (at time points when LC-MS/MS data was planned to be available only) and the proportion with castration maintained at Day 183 (after receiving 2 S.C. administrations of triptorelin pamoate, three months apart); they were calculated along with their respective 95% confidence intervals (CI) using exact methods on the ITT population at Day 29 and on the initially castrated (IC) population at Day 183
| Percentage of subjects | Triptorelin Pamoate |
|---|---|
| Day 29 (N=126) | 97.6 (93.2 to 99.5) |
| Day 183 (N=119) | 96.6 (91.6 to 99.1) |
Percentage of subjects demonstrating castration at Day 92 (before administration of the second dose) were also assessed using the LC-MS/MS method and missing data imputed by immunoassay method (at time points when LC-MS/MS data was planned to be available only) and summarised using descriptive statistics on the ITT and IC populations.
| Percentage of subjects | Triptorelin Pamoate |
|---|---|
| Percentage of Subjects Demonstrating Castration Before Administration of the Second Dose | 99.2 (95.4 to 100) |
Probability of testosterone \<50 ng/dL from Day 29 to Day 183 was assessed as a secondary endpoint using the time to event from first administration date to first observed (and subsequently confirmed if assessment not performed at end of study or early withdrawal visits) serum testosterone level ≥50 ng/dL or ≥1.735 nmol/L at or after Day 29, assessed using the LC-MS/MS Method and Missing Data imputed by immunoassay method Kaplan-Meier Analysis. LC-MS/MS: Liquid Chromatography-Tandem Mass Spectrometry
| Proportion of subjects | Triptorelin Pamoate |
|---|---|
| Probability of Testosterone <50 ng/dL | 0.96 (0.92 to 0.99) |
Percentage of subjects demonstrating castration at Day 95 (3-4 days after administration of the second dose to assess the suppression of acute-on-chronic effect following the second administration) were also assessed using the LC-MS/MS method and missing data imputed by immunoassay method (at time points when LC-MS/MS data was planned to be available only) and summarised using descriptive statistics on the ITT and IC populations.
| Percentage of subjects | Triptorelin Pamoate |
|---|---|
| Percentage of Subjects Demonstrating Castration With Testosterone Level <50 ng/dL at Day 95 | 98.3 (94.1 to 99.8) |
Time to castration (Tcast) from first administration date until first observed serum testosterone level \<50 ng/dL or \<1.735 nmol/L evaluated using the immunoassay method only (i.e. defined as the number of days between the injection time at Day 1 and castration achievement)
| Day | Triptorelin Pamoate |
|---|---|
| Time to Achieve Castration (Tcast) | 22 (22 to 23) |
Minimal triptorelin plasma concentration at the end of each dosage interval just before the next dose injection (Cmin) for Days 92 and 183 were assessed.
| ng/mL | Triptorelin Pamoate |
|---|---|
| Day 92 | 0.062 ± 0.031 |
| Day 183 (N=117) | 0.049 ± 0.027 |
Serum PSA level was presented throughout the study using descriptive statistics displaying raw values, change from Baseline and percentage change from Baseline at each visit in all subjects from the ITT population only. Additionally, the PSA level was described in subjects with elevated PSA levels (i.e. \>4 ng/mL) at study entry, and the proportion of subjects with normal PSA levels (i.e. \[0-4\] ng/mL) at Day 183 compared to Baseline was presented.
| Percentage Change | Triptorelin Pamoate |
|---|---|
| Percentage Change in Prostate Specific Antigen (PSA) Levels From Baseline in All Subjects | -85.503 ± 42.410 |
0-4 ng/mL (normal PSA value) \>4 ng/mL (abnormal PSA levels)
| Percentage of subjects | Triptorelin Pamoate |
|---|---|
| End of Study (0-4 ng/mL) | 84.6 |
| End of Study (>4 ng/mL) | 15.4 |
Tumour progression was recorded according to the Investigator's clinical judgement, considering the PSA levels and any other indications of disease; the clinical confirmation might be supplemented by radiological or other investigations or scans if required. The lack of clinically apparent tumour progression was assessed at Day 92 (prior to administration of the second dose) and Day 183 (end of study visit).
| participants | Triptorelin Pamoate |
|---|---|
| Day 92: Non Progressive Disease | 122 |
| Day 92: Progressive Disease | 0 |
| Day 183: Non Progressive Disease | 114 |
| Day 183: Progressive Disease | 3 |
| Percentage of subjects | Triptorelin Pamoate |
|---|---|
| Any Adverse Events | 35.7 |
| Any Serious Adverse Events (SAEs) | 4.8 |
| Any Treatment Emergent Adverse Events (TEAEs) | 35.7 |
| TEAEs Leading to Withdrawal | 0.8 |
| TEAEs Leading to Death | 0.8 |
| Maximum Grade NCI-CTC of TEAEs: Grade 5 | 0.8 |
| Maximum Grade NCI-CTC of TEAEs: Grade 4 | 0 |
| Maximum Grade NCI-CTC of TEAEs: Grade 3 | 4.0 |
| Maximum Grade NCI-CTC of TEAEs: Grade 2 | 13.5 |
| Maximum Grade NCI-CTC of TEAEs: Grade 1 | 27.8 |
| Most serious causality of TEAEs: Related | 21.4 |
| Most serious causality of TEAEs: Not related | 26.2 |
| Hours | Triptorelin Pamoate |
|---|---|
| Time to Cmax (Tmax) of Triptorelin | 4.5 (1.01 to 24) |
| ng/mL | Triptorelin Pamoate |
|---|---|
| Peak Plasma Concentration Value (Cmax) of Triptorelin | 18.58 ± 7.35 |
| h*ng/mL | Triptorelin Pamoate |
|---|---|
| Area Under the Concentration Versus Time Curve Between 0 and 24 Hours (AUC0-24) of Triptorelin | 304.6 ± 103.7 |
| ng/mL | Triptorelin Pamoate |
|---|---|
| Day 92 (N=14) | 0.078 ± 0.038 |
| Day 183 (N=18) | 0.062 ± 0.023 |
Collected over Up to Day 183. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Triptorelin Pamoate 11.25 mg | — | 6/126 (4.8%) | 45/126 (35.7%) |
| Event | Triptorelin Pamoate 11.25 mg |
|---|---|
| PneumoniaInfections and infestations | 2/126 |
| Fibula FractureInjury, poisoning and procedural complications | 1/126 |
| Cardiac FailureCardiac disorders | 1/126 |
| Myocardial infarctionCardiac disorders | 1/126 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 1/126 |
| AnaemiaBlood and lymphatic system disorders | 1/126 |
| Event | Triptorelin Pamoate 11.25 mg |
|---|---|
| Hot FlushVascular disorders | 13/126 |
| Weight IncreasedInvestigations | 12/126 |
| Weight DecreasedInvestigations | 7/126 |
| HypertensionVascular disorders | 6/126 |
| HeadacheNervous system disorders | 4/126 |
| Erectile DysfunctionReproductive system and breast disorders | 3/126 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 3/126 |
| Oedema PeripheralGeneral disorders | 2/126 |
| Breast PainReproductive system and breast disorders | 2/126 |
| FallInjury, poisoning and procedural complications | 2/126 |
| Age, Continuous(years) | Triptorelin Pamoate |
|---|---|
| Mean | 70.4 ± 7.3 |
| Sex/Gender, Customized(participants) | Triptorelin Pamoate |
|---|---|
| Male | 126 |
| Race/Ethnicity, Customized(participants) | Triptorelin Pamoate |
|---|---|
| Caucasian / White | 120 |
| Missing | 6 |
| Height(cm) | Triptorelin Pamoate |
|---|---|
| Mean | 172.2 ± 6.7 |
| Weight(kg) | Triptorelin Pamoate |
|---|---|
| Mean | 80.6 ± 12.8 |
| Body Mass Index (BMI)(kg/m²) | Triptorelin Pamoate |
|---|---|
| Mean | 27.16 ± 3.96 |
| Prostate Specific Antigen (PSA)(ng/mL) | Triptorelin Pamoate |
|---|---|
| Mean | 133.53 ± 385.60 |
The record gives a start of Jan 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triptorelin